Owkin’s Post

FDA Clears Proscia’s AI-Powered Digital Pathology Solution for Cancer Diagnosis - HIT Consultant #FDA Clears Proscia’s AI-Powered Digital Pathology Solution for Cancer Diagnosis The FDA has cleared Proscia's AI-powered digital pathology solution for cancer diagnosis. The solution, called Concentriq Dx, uses artificial intelligence to analyze and interpret digital pathology images. It can assist pathologists in detecting and diagnosing cancer more accurately and efficiently. Concentriq Dx has been trained on a large dataset of pathology images and uses deep learning algorithms to provide insights and recommendations to pathologists. The FDA clearance of Concentriq Dx marks a significant milestone in the use of AI in cancer diagnosis. #The Role of AI in Cancer Diagnosis AI has the potential to revolutionize cancer diagnosis by improving accuracy and efficiency. It can analyze large amounts of ai.mediformatica.com #proscia #digital #pathology #digitalpathology #laboratories #cancer #clinical #diagnosis #diagnostic #efficiency #provider #acce #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/3T4aNet)

Roche has announced the introduction of a Digital Pathology Open Environment, leveraging AI-based tools to enhance cancer patients' care with 9 partners (see below). Sapien Biosciences wide range of high quality cancer samples, metadata including #NGS data, treatment and survival data, combined with pathology assays and high-resolution whole slide scanners for image analysis, can accelerate algorithm development for #precisionmedicine. For example, Roche's 9 partners are: DeepBio Group: Algorithm for #prostatecancer detection, grading, and tumour quantification DiaDeep: Algorithms for #breastcancer biomarker quantification Lunit: Tumour proportion score (TPS) analysis for non-small cell #lungcancer Mindpeak: Algorithms for breast #biomarkers and pan tumour PD-L1 for #lung, #gastric, #esophageal, #bladder and breast cancers Owkin: Algorithm for the screening of microsatellite stability in #colorectalcancer Qritive: Algorithms for screening and grading of prostate cancer, analysing lymph nodes for #metastasis, and #screening for colon cancer Sonrai Analytics: Algorithm for determining microsatellite instability (MSI) status in colorectal cancer Stratipath: Algorithm for risk profiling of invasive #breastcancer #Healthcare #DigitalPathology #AI #ML #PatientCare #biobank #FFPE #DEI #Asian

Check out this really interesting article on the use of AI in oncology! I love using ChatGPT and AI for trip planning & general info gathering but we're also seeing greater development and potential uses in clinical trial design, biomarker identification, and sorting through large amounts of data. #AI #oncology #cancercare #clinicaltrials

🎉𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐢𝐧𝐠 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐂𝐚𝐫𝐞: 𝐆𝐄 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐋𝐚𝐮𝐧𝐜𝐡𝐞𝐬 𝐀𝐈 𝐀𝐩𝐩 𝐟𝐨𝐫 𝐄𝐧𝐡𝐚𝐧𝐜𝐞𝐝 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐢𝐬!🩺 GE HealthCare Technologies is set to introduce CareIntellect for Oncology in 2025, focusing on prostate and breast cancers. This AI application aims to streamline cancer diagnosis and treatment by providing quick access to relevant patient data and identifying potential clinical trials. 🗂️💡 In conjunction with the launch, GE has established an AI innovation lab to accelerate developments in healthcare technology. Taha Kass-Hout, MD, MS, GE’s Global Chief Science and Technology Officer, highlighted the commitment to integrating AI into medical devices for better patient outcomes. 🔗 Read More - https://lnkd.in/diSwPH8m 🖊️ Written By - Nikita Saha #GEHealthcare #Oncology #AI #HealthcareTech #MedTech #AIInHealthcare #CancerCareInnovation #TechForGood #DigitalHealth #AIForOncology #SmartHealthcare #FutureOfMedTech #HealthcareRevolution #CancerTreatmentTech

Our AI #Innovation Platform focuses on leveraging the power of this technology to develop oncology #therapeutics - but AI can also be applied for diagnostic purposes, as highlighted by 3️⃣ exciting recent developments: 1️⃣ Scientists from Germany developed an AI platform that enables fully automated analysis of tissue sections from #lungcancer patients to improve diagnosis accuracy 👉 https://lnkd.in/ePhFwvy4 2️⃣ Researchers from Spain and Guangzhou developed a novel deep learning method called “artificial intelligence of the nucleus,” which can identify specific nuclear signatures of cancer and other disease conditions at nanoscale resolution. They also applied #interpretableAI to identify key biological features recognized by the algorithm 👉 https://lnkd.in/ePJBpCDJ 3️⃣ The Dutch company WSK Medical and the Portuguese company IMP Diagnostics received a Eurostars grant to further develop an advanced AI solution for the automated analysis of the tumor-stroma ratio in #coloncancer tissue 👉 https://lnkd.in/e-GhTGJb Together, these articles underline that #ArtificialIntelligence is increasingly investigated as a tool to improve management of #cancer healthcare. 💡 Do you want to learn how you can gain access to AI expertise by working with Oncode Accelerator? Read about the unique cancer #research infrastructure and #cofunding that we offer here 👉 https://lnkd.in/ewzz-d5E #oncology #oncologyresearch #AIforgood #oncologynews #oncodeaccelerator #cancerresarch

The ever-growing field of artificial intelligence (AI) is having a profound impact on oncology. This article delves into both the current applications of AI in cancer treatment, such as analyzing medical images for tumor detection and personalizing treatment plans, and the exciting possibilities it holds for the future. By leveraging vast datasets and machine learning algorithms, AI has the potential to revolutionize early cancer screening, usher in a new era of precision medicine, and optimize healthcare delivery for cancer patients. Read more 👉https://lnkd.in/eq8EHZZ7 #AIinOncology #ML #AIinHealthcareDelivery #BigData #Automate #Technology #AI #HealthcareInnovation #ConversationalAI #ArtificialIntelligence #Australia #Innovate with SHAVIK Visit www.SHAVIK.ai

[#Lunit #Oncology] Here is our latest #publication in #BreastCancerResearch, featuring #AI analysis of #HER2 and ER/PR. The study aimed to evaluate the role of #LunitSCOPE in enhancing pathologists’ consistency and accuracy of #breastcancer molecular subtype classification, including expression levels of HER2, ER, and PR. The results showed that Lunit SCOPE HER2 and ER/PR significantly improve pathologists' concordance, increasing agreement among #pathologists on the status of HER2, ER, and PR, especially in cases with intermediate weakly positive expressions. Notably, AI assistance led to an increase in agreement on HER2 status from 49.3% to 74.1%, ER from 93.0% to 96.5%, and PR from 84.6% to 91.5%. These solutions hold great potential to enhance #treatmentstrategies and ensure more accurate and personalized approaches for patients. Read the publication or reach out to us at oncology@lunit.io to learn more. Link to the publication: https://lnkd.in/dNJ-v7xD Congratulations to the team! 🎉 Soo ick Cho Taebum Lee Sanghoon Song Gahee Park Heon Song Jongchan Park Sérgio Pereira Donggeun Yoo Keunhyung Chung Siraj A. #digitalpathology #BCR #cancer #cancertreatment #personalizedtreatment #medicalAI

Medical advances utilizing AI will change the world

PathAI, a pioneering AI and digital pathology solutions provider, has launched MET Predict on its AISight Image Management System (IMS). This AI-powered algorithm is designed to identify non-small cell lung cancer (NSCLC) tumors likely harboring MET exon 14 skipping (METex14) or MET amplification from H&E whole slide images. NSCLC accounts for approximately 85% of lung cancers, with 3-4% involving METex14 and 1-6% exhibiting MET amplification. Targeted therapies for METex14-positive NSCLC patients are available, while MET amplification is an emerging biomarker. 'The integration of MET Predict into AISight marks a significant leap forward in utilizing AI to enhance the efficiency of NSCLC tumor assessments, particularly in identifying those with potential genetic alterations,' said Andy Beck, MD, PhD, co-founder and CEO of PathAI. MET Predict can identify over 90% of MET-altered tumors while providing insights that may preserve tissue in 30% of cases with low MET alteration likelihood. This innovation addresses the need for accessible, rapid, and comprehensive molecular tools that provide actionable insights from biopsy samples. #PathAI #AISight #METPredict #NSCLC #LungCancer #DigitalPathology #AI PathAI

MIT researchers have developed an AI model capable of detecting breast cancer up to 5 years before clinical diagnosis, potentially revolutionizing early intervention and saving countless lives. Here's a breakdown of this groundbreaking technology: ✔The AI analyzed chromatin images from 560 tissue samples across 122 patients, identifying 8 distinct cell states throughout various stages of ductal carcinoma in situ (DCIS). ✔The model considers both cellular composition and spatial arrangement, revealing that tissue organization is crucial in predicting disease progression. ✔Utilizing a convolutional variational autoencoder, the AI learns from simple chromatin staining images - a more cost-effective and accessible method compared to complex sequencing techniques. ✔Remarkably, the model detected cell states associated with invasive cancer even in tissue that appeared normal to the human eye. With current 5-year survival rates for breast cancer at approximately 90% when detected early, this 5-year head start on diagnosis and treatment could significantly improve patient outcomes. However, this breakthrough is just the tip of the iceberg. The potential impact of AI on healthcare in the coming decade is likely to surpass most expectations. From early disease detection to personalized treatment plans and drug discovery, AI is poised to transform medical practice and patient care in ways we're only beginning to imagine. As we continue to harness the power of AI in medicine, we're not just improving healthcare - we're redefining what's possible in our fight against diseases like cancer.